(Q39654887)

13 September 2017

title

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers (English)

1 reference

13 September 2017

0 references

1 reference

Lei Wu

1

1 reference

13 September 2017

Anastasia Parton

2

1 reference

13 September 2017

Ling Lu

3

1 reference

13 September 2017

Mary Adams

4

1 reference

13 September 2017

Peter Schafer

5

1 reference

13 September 2017

J Blake Bartlett

6

1 reference

13 September 2017

publication date

17 September 2010

1 reference

Cancer Immunology, Immunotherapy

13 September 2017

published in

1 reference

13 September 2017

volume

60

1 reference

13 September 2017

issue

1

1 reference

13 September 2017

page(s)

61-73

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-010-0919-9

13 September 2017

exact match

0 references

cites work

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0919-9

10.1007/S00262-010-0919-9

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference